ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute ...
MedPage Today on MSN
Here's the Data Supporting Pegcetacoplan's Approval in Two Rare Kidney Diseases
Affecting roughly 5,000 people in the U.S., C3 glomerulopathy and immune-complex MPGN are two rare glomerulopathies ...
Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906).
Aethlon’s Hemopurifier is designed to bind and remove harmful EVs from blood through a combination of plasma separation, size exclusion, and binding to a proprietary affinity resin containing plant ...
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, announced today the 20 November 2025 public ...
Aethlon Medical’s Hemopurifier® is an investigational extracorporeal device designed to bind and remove harmful EVs from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback